









Markets
/
Stocks
/
nasdaq-nvo
/

Novo Nordisk A/S

NVO

View Detailed Chart

79.880USD

-1.170-1.44%

Close 06/13, 16:00（ET）Quotes delayed by 15 min

268.72BMarket Cap

18.34P/E TTM



Novo Nordisk A/S

79.880

-1.170-1.44%

Company

Intraday

30m

Today

-1.44%

5 Days

+7.03%

1 Month

+24.02%

6 Months

-25.31%

Year to Date

-7.14%

1 Year

-43.94%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 16 analysts

BUY

Current Rating

91.679

Target Price

14.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

167

Total

Median

Average

Company name

Ratings

Analysts

Novo Nordisk A/S

NVO

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(3)

Neutral(1)

Buy(7)

Indicators

Sell(2)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

2.039

Buy

RSI(14)

68.311

Neutral

STOCH(KDJ)(9,3,3)

89.002

Overbought

ATR(14)

2.394

Low Volatility

CCI(14)

116.813

Buy

Williams %R

12.253

Overbought

TRIX(12,20)

0.686

Sell

StochRSI(14)

44.068

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

78.880

Buy

MA10

75.746

Buy

MA20

72.038

Buy

MA50

67.376

Buy

MA100

74.536

Buy

MA200

92.674

Sell

News

Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Though oncology remains the largest therapeutic area in the pharmaceutical industry, the weight management field has caught fire in the past few years. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest...

OtherThu, May 22

Trump Plans Major Drug Price Cuts, Pharma Stocks Tumbles

Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.

TradingKeyMon, May 12

Darkest Hour for U.S. Biotech Stocks! Top FDA Vaccine Official Resigns, Wall Street Slams HHS Secretary RFK Jr.

TradingKey - With the appointment of vaccine skeptic Robert F. Kennedy Jr. (RFK Jr.) as U.S. Secretary of Health and Human Services, coupled with the forc

TradingKeyTue, Apr 1

U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Microsoft

March 13 (Reuters) - U.S. stock index futures declined on Thursday as investors closely monitored a stopgap government funding bill amid escalating slowdown fears driven by President Donald Trump's chaotic tariff policies. .N

ReutersThu, Mar 13

Facing a Trumpcession: What Options Remain for Stock Investors?

TradingKey - While Wednesday's CPI data came in below expectations, alleviating some market fears, intra-day trading remained volatile, indicating that investors are still seeking more data for further assessment.

TradingKeyWed, Mar 12

Company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Ticker SymbolNVO

CompanyNovo Nordisk A/S

CEOMr. Lars Fruergaard Joergensen

Websitehttps://www.novonordisk.com/